Shanghai Pharmaceuticals Holding Co., Ltd is principally engaged in the manufacture and sale of pharmaceuticals.
Quote | Shanghai Pharmaceuticals Holding Co Ltd ADR Repstg Shs H (OTCMKTS:SHPMY)
Last: | $6.90 |
---|---|
Change Percent: | -5.09% |
Open: | $6.891 |
Close: | $7.27 |
High: | $6.9 |
Low: | $6.891 |
Volume: | 371 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Shanghai Pharmaceuticals Holding Co Ltd ADR Repstg Shs H (OTCMKTS:SHPMY)
2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...
Summary Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones - the third ADC deal between the two companies this year. LianBio announced that Pfizer will...
Message Board Posts | Shanghai Pharmaceuticals Holding Co Ltd ADR Repstg Shs H (OTCMKTS:SHPMY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Shanghai Pharmaceuticals Holding Co Ltd ADR Repstg Shs H Company Name:
SHPMY Stock Symbol:
OTCMKTS Market:
SHENZHEN and SHANGHAI , August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of n...
SHANGHAI , Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining an...
SHANGHAI , April 15, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holdings Co . Ltd. (Shanghai Pharma or "the Company") (601607.SH ) ( 2067.HK), a major Chinese pharmaceutical group, has unveiled stock option incentive plans in a milestone move designed to accelerate restructuring ...